142 related articles for article (PubMed ID: 36963666)
21. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
23. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma.
Abraha I; Aristei C; Palumbo I; Lupattelli M; Trastulli S; Cirocchi R; De Florio R; Valentini V
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD002102. PubMed ID: 30284239
[TBL] [Abstract][Full Text] [Related]
24. Prostate radiotherapy and the risk of secondary rectal cancer-a meta-analysis.
Nugent TS; Low EZ; Fahy MR; Donlon NE; McCormick PH; Mehigan BJ; Cunningham M; Gillham C; Kavanagh DO; Kelly ME; Larkin JO
Int J Colorectal Dis; 2022 Feb; 37(2):437-447. PubMed ID: 35037077
[TBL] [Abstract][Full Text] [Related]
25. Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort.
Wallis CJD; Huang LC; Zhao Z; Penson DF; Koyama T; Conwill R; Tallman JE; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Barocas DA; Hoffman KE
Urol Oncol; 2022 Feb; 40(2):56.e1-56.e8. PubMed ID: 34154899
[TBL] [Abstract][Full Text] [Related]
26. Primary cryotherapy for localised or locally advanced prostate cancer.
Jung JH; Risk MC; Goldfarb R; Reddy B; Coles B; Dahm P
Cochrane Database Syst Rev; 2018 May; 5(5):CD005010. PubMed ID: 29845595
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy.
Yang ST; Liu HH; Liu CH; Wang LW; Wang PH
Int J Gynaecol Obstet; 2024 May; ():. PubMed ID: 38746971
[TBL] [Abstract][Full Text] [Related]
28. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
29. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
Greenberger BA; Zaorsky NG; Den RB
Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
[TBL] [Abstract][Full Text] [Related]
31. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
32. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
33. Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials.
Holch P; Henry AM; Davidson S; Gilbert A; Routledge J; Shearsmith L; Franks K; Ingleson E; Albutt A; Velikova G
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):495-510. PubMed ID: 28126299
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials.
Guo W; Sun YC; Bi JQ; He XY; Xiao L
BMC Cancer; 2019 Nov; 19(1):1063. PubMed ID: 31703647
[TBL] [Abstract][Full Text] [Related]
35. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
Leeman JE; Shin KY; Chen YH; Mak RH; Nguyen PL; D'Amico AV; Martin NE
Cancer; 2023 Oct; 129(19):3044-3052. PubMed ID: 37485697
[TBL] [Abstract][Full Text] [Related]
36. Definitive pelvic radiotherapy for patients with newly diagnosed stage IVB cervical cancer: a systematic review.
Viveros-Carreño D; Vieira-Serna S; Grillo-Ardila CF; Rodriguez J; Mora-Soto N; Jhingran A; Ramirez PT; Pareja R
Int J Gynecol Cancer; 2023 Jul; 33(7):1057-1062. PubMed ID: 37192760
[TBL] [Abstract][Full Text] [Related]
37. Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.
Murthy V; Maitre P; Kannan S; Panigrahi G; Krishnatry R; Bakshi G; Prakash G; Pal M; Menon S; Phurailatpam R; Mokal S; Chaurasiya D; Popat P; Sable N; Agarwal A; Rangarajan V; Joshi A; Noronha V; Prabhash K; Mahantshetty U
J Clin Oncol; 2021 Apr; 39(11):1234-1242. PubMed ID: 33497252
[TBL] [Abstract][Full Text] [Related]
38. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer.
Chrouser KL; Leibovich BC; Sweat SD; Larson DW; Davis BJ; Tran NV; Zincke H; Blute ML
J Urol; 2005 Jun; 173(6):1953-7. PubMed ID: 15879789
[TBL] [Abstract][Full Text] [Related]
39. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
